|
1
|
Borel F, Han R, Visser A, et al; Réseau
Centre de Ressources Biologiques Foie (French Liver Biobanks
Network), France. Adenosine triphosphate-binding cassette
transporter genes up-regulation in untreated hepatocellular
carcinoma is mediated by cellular microRNAs. Hepatology.
55:821–832. 2012.
|
|
2
|
van Oosterwijk JG, Herpers B, Meijer D, et
al: Restoration of chemosensitivity for doxorubicin and cisplatin
in chondrosarcoma in vitro: BCL-2 family members cause
chemoresistance. Ann Oncol. 23:1617–1626. 2012.PubMed/NCBI
|
|
3
|
Zhu W, Xu H, Zhu D, et al: miR-200bc/429
cluster modulates multidrug resistance of human cancer cell lines
by targeting BCL2 and XIAP. Cancer Chemother Pharmacol. 69:723–731.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhu W, Zhu D, Lu S, et al: miR-497
modulates multidrug resistance of human cancer cell lines by
targeting BCL2. Med Oncol. 29:384–391. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lieber J, Kirchner B, Eicher C, Warmann
SW, Seitz G, Fuchs J and Armeanu-Ebinger S: Inhibition of Bcl-2 and
Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Pediatr Blood Cancer. 55:1089–1095. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wesarg E, Hoffarth S, Wiewrodt R, Kröll M,
Biesterfeld S, Huber C and Schuler M: Targeting BCL-2 family
proteins to overcome drug resistance in non-small cell lung cancer.
Int J Cancer. 121:2387–2394. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mallick S, Patil R, Gyanchandani R, Pawar
S, et al: Human oral cancers have altered expression of Bcl-2
family members and increased expression of the anti-apoptotic
splice variant of Mcl-1. J Pathol. 217:398–407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma B, Zhang H, Wang J, Zhang B, Xu X and
Cheng B: HIV-1 viral protein R (Vpr) induction of apoptosis and
cell cycle arrest in multidrug-resistant colorectal cancer cells.
Oncol Rep. 28:358–364. 2012.PubMed/NCBI
|
|
9
|
Di Leva G and Croce CM: Roles of small
RNAs in tumor formation. Trends Mol Med. 16:257–267.
2010.PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Slaby O, Bienertova-Vasku J, Svoboda M and
Vyzula R: Genetic polymorphisms and microRNAs: new direction in
molecular epidemiology of solid cancer. J Cell Mol Med. 16:8–21.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yin J, Tang HF, Xiang Q, Yu J, Yang XY, Hu
N and Lei XY: MiR-122 increases sensitivity of drug-resistant
BEL-7402/5-FU cells to 5-fluorouracil via down-regulation of bcl-2
family proteins. Pharmazie. 66:975–981. 2011.PubMed/NCBI
|
|
13
|
Yang X, Yin J, Yu J, et al: miRNA-195
sensitizes human hepatocellular carcinoma cells to 5-FU by
targeting BCL-w. Oncol Rep. 27:250–257. 2012.PubMed/NCBI
|
|
14
|
Hou J, Lin L, Zhou W, et al:
Identification of miRNomes in human liver and hepatocellular
carcinoma reveals miR-199a/b-3p as therapeutic target for
hepatocellular carcinoma. Cancer Cell. 19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J, Cheng C, He CL, Zhou YJ and Cao
Y: The expression of Bcl-XL, Bcl-XS and p27Kip1 in
topotecan-induced apoptosis in hepatoblastoma HepG2 cell line.
Cancer Invest. 26:456–463. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao Y, Zhang CL, Zeng BF, Wu XS, Gao TT
and Oda Y: Enhanced chemosensitivity of drug-resistant osteosarcoma
cells by lentivirus-mediated Bcl-2 silencing. Biochem Biophys Res
Commun. 390:642–647. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lagos-Quintana M, Rauhut R, Lendeckel W
and Tuschl T: Identification of novel genes coding for small
expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Johnson SM, Grosshans H, Shingara J, et
al: RAS is regulated by let-7 microRNA family. Cell. 120:635–647.
2005. View Article : Google Scholar
|
|
19
|
Sampson VB, Rong NH, Han J, et al:
MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth
in Burkitt lymphoma cells. Cancer Res. 67:9762–9770. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee YS and Dutta A: The tumor suppressor
microRNA let-7 represses the HMGA2 oncogene. Genes Dev.
21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Johnson CD, Esquela-Kerscher A, Stefani G,
et al: The let-7 microRNA represses cell proliferation pathways in
human cells. Cancer Res. 67:7713–7722. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Büssing I, Slack FJ and Grosshans H: let-7
microRNAs in development, stem cells and cancer. Trend Mol Med.
14:400–409. 2008.
|
|
23
|
Shimizu S, Takehara T, Hikita H, et al:
The let-7 family of microRNAs inhibits Bcl-xL expression and
potentiates sorafenib-induced apoptosis in human hepatocellular
carcinoma. J Hepatol. 52:698–704. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qin B, Xiao B, Liang D, Li Y, Jiang T and
Yang H: MicroRNA let-7c inhibits Bcl-xl expression and regulates
ox-LDL-induced endothelial apoptosis. BMB Rep. 45:464–469. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hummel R, Hussey DJ and Haier J:
MicroRNAs: predictors and modifiers of chemo- and radiotherapy in
different tumour types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nicoloso MS, Sun H, Spizzo R, et al:
Single-nucleotide polymorphisms inside microRNA target sites
influence tumor susceptibility. Cancer Res. 70:2789–2798. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mishra PJ and Bertino JR: MicroRNA
polymorphisms: the future of pharmacogenomics, molecular
epidemiology and individualized medicine. Pharmacogenomics.
10:399–416. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smits KM, Paranjape T, Nallur S, et al: A
let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage
colorectal cancer. Clin Cancer Res. 17:7723–7731. 2011.
|
|
29
|
Zhang L, Liu Y, Song F, et al: Functional
SNP in the microRNA-367 binding site in the 3′UTR of the calcium
channel ryanodine receptor gene3 (RYR3) affects breast cancer risk
and calcification. Proc Natl Acad Sci USA. 108:13653–13658.
2011.PubMed/NCBI
|
|
30
|
Pharoah PD, Palmieri RT, Ramus SJ, et al:
The role of KRAS rs61764370 in invasive epithelial ovarian cancer:
implications for clinical testing. Clin Cancer Res. 17:3742–3750.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu Y, Xiao Y, Ding X, Zhuo Y, Ren P, Zhou
C and Zhou J: A miR-200b/200c/429-binding site polymorphism in the
3′ untranslated region of the AP-2α gene is associated with
cisplatin resistance. PLoS One. 6:e290432011.PubMed/NCBI
|
|
32
|
Peddaboina C, Jupiter D, Fletcher S, et
al: The downregulation of Mcl-1 via USP9X inhibition sensitizes
solid tumors to Bcl-xl inhibition. BMC Cancer. 12:5412012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bansal H, Seifert T, Bachier C, Rao M,
Tomlinson G, Iyer SP and Bansal S: The transcription factor Wilms
tumor 1 confers resistance in myeloid leukemia cells against the
proapoptotic therapeutic agent TRAIL (tumor necrosis factor
α-related apoptosis-inducing ligand) by regulating the
antiapoptotic protein Bcl-xL. J Biol Chem. 287:32875–32880.
2012.PubMed/NCBI
|
